Brief: Cognition Doses First Patient With Dementia With Lewy Bodies In Phase 2 Clinical Study Of CT1812
23/06/2022 12:39
June 23 (Reuters) - Cognition Therapeutics Inc CGTX.O :
* COGNITION THERAPEUTICS DOSES FIRST PATIENT WITH DEMENTIA
WITH
LEWY BODIES IN PHASE 2 CLINICAL STUDY OF CT1812
Source text for Eikon: ID:nGNX6F4s14
Further company coverage: CGTX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cognition Therapeutics
See all newsU.S. STOCKS ON THE MOVE-Quest Diagnostics, Tractor Supply, Dutch Bros
U.S. STOCKS ON THE MOVE-CME, Lockheed Martin, Valero Energy
Cognition rises after FDA backs late-stage trial plan for dementia drug
Brief: Cognition Therapeutics Announces Issuance Of Composition Of Matter Patent, Extending Protection For Zervimesine (CT1812) Through 2045
Brief: Cognition Therapeutics Schedules A Type C Meeting With FDA To Align On Endpoints For Phase 3 Trial Of Zervimesine (Ct1812) In DLB